NASDAQ:GRCE
Grace Therapeutics, Inc.
Grace Therapeutics, Inc. reported net income of −$7.8M in fiscal 2026. The diluted share count rose 36.6%.Summary generated from Grace Therapeutics, Inc.'s SEC filings. Latest annual report filed Jun 18, 2026.
Key statistics
Fiscal 2026 from SEC filings. MethodologyRevenue (FY26)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−11.9%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+36.6%
Financials
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | 100 | n/a | n/a | n/a | n/a |
| Operating income | −16 | −52 | −13 | −17 | −11 |
| Net income | −10 | −42 | −13 | −10 | −8 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 4Insider transaction report
Oct 5, 2026 - 4Insider transaction report
Oct 1, 2026 - 8-KResults of a shareholder vote
Sep 18, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KEntry into a material agreement
Aug 6, 2026 - DEF 14AProxy statement
Jul 28, 2026 - 8-KOther events
Jul 28, 2026